company background image
ORIC

ORIC Pharmaceuticals NasdaqGS:ORIC Stock Report

Last Price

US$4.84

Market Cap

US$191.1m

7D

4.5%

1Y

-74.0%

Updated

12 Aug, 2022

Data

Company Financials +
ORIC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ORIC Stock Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.

ORIC Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ORIC Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.84
52 Week HighUS$26.70
52 Week LowUS$2.62
Beta1.04
1 Month Change9.50%
3 Month Change72.24%
1 Year Change-74.02%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.22%

Recent News & Updates

Aug 11

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

ORIC Pharmaceuticals press release (NASDAQ:ORIC): Q2 GAAP EPS of -$0.51 beats by $0.09. Cash, cash equivalents and investments totaled $237.8 million

Jun 24
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ORICUS BiotechsUS Market
7D4.5%1.2%3.2%
1Y-74.0%-21.7%-10.1%

Return vs Industry: ORIC underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: ORIC underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is ORIC's price volatile compared to industry and market?
ORIC volatility
ORIC Average Weekly Movement16.6%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ORIC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: ORIC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201479Jacob Chackohttps://www.oricpharma.com

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms.

ORIC Pharmaceuticals Fundamentals Summary

How do ORIC Pharmaceuticals's earnings and revenue compare to its market cap?
ORIC fundamental statistics
Market CapUS$191.07m
Earnings (TTM)-US$84.64m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORIC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$84.64m
Earnings-US$84.64m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did ORIC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ORIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ORIC?

Other financial metrics that can be useful for relative valuation.

ORIC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does ORIC's PB Ratio compare to its peers?

ORIC PB Ratio vs Peers
The above table shows the PB ratio for ORIC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average6.6x
SBTX Silverback Therapeutics
0.6x12.7%US$180.1m
CVM CEL-SCI
4x69.6%US$180.7m
FENC Fennec Pharmaceuticals
14.4x79.2%US$180.7m
SPPI Spectrum Pharmaceuticals
7.1x67.3%US$238.9m
ORIC ORIC Pharmaceuticals
0.8x-22.6%US$191.1m

Price-To-Book vs Peers: ORIC is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (6.6x).


Price to Earnings Ratio vs Industry

How does ORIC's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: ORIC is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is ORIC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ORIC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ORIC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ORIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ORIC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ORIC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is ORIC Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-22.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ORIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ORIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ORIC is forecast to have no revenue next year.

High Growth Revenue: ORIC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORIC is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has ORIC Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-32.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ORIC is currently unprofitable.

Growing Profit Margin: ORIC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORIC is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.

Accelerating Growth: Unable to compare ORIC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORIC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: ORIC has a negative Return on Equity (-35.73%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is ORIC Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ORIC's short term assets ($233.5M) exceed its short term liabilities ($12.5M).

Long Term Liabilities: ORIC's short term assets ($233.5M) exceed its long term liabilities ($10.3M).


Debt to Equity History and Analysis

Debt Level: ORIC is debt free.

Reducing Debt: ORIC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORIC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ORIC has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 30.3% each year.


Discover healthy companies

Dividend

What is ORIC Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORIC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ORIC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Jacob Chacko (43 yo)

4.25yrs

Tenure

US$6,975,924

Compensation

Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko has served as chairman of th...


CEO Compensation Analysis

Compensation vs Market: Jacob's total compensation ($USD6.98M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Jacob's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ORIC's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: ORIC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ORIC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ORIC Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ORIC Pharmaceuticals, Inc.
  • Ticker: ORIC
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$191.075m
  • Shares outstanding: 39.48m
  • Website: https://www.oricpharma.com

Number of Employees


Location

  • ORIC Pharmaceuticals, Inc.
  • 240 East Grand Avenue
  • 2nd Floor
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.